Skip to main content
. 2020 Jul 15;1(4):100074. doi: 10.1016/j.jtocrr.2020.100074

Figure 5.

Figure 5

(A) Response rate, (B) PFS, and (C) OS to immunotherapy in patients with irAEs according to corticosteroid administration and in those without irAEs. irAE, immune-related adverse event; OS, overall survival; PFS, progression-free survival.